Abstract: The invention is directed to a food product for use in the prevention, inhibition or treatment of tooth decay and other dental conditions, diseases and disorders, wherein said food product is a chewing gum comprising at least one cannabinoid.

Abstract: Provided herein injectable implant compositions useful for acceleration of bone fracture healing, treatment of dental or oral pathologies, and controlled drug delivery.

Abstract: Compositions comprising magnesium enriched liquids re provided. Specifically, compositions comprising magnesium enriched milk and/or milk product, wherein a concentration of magnesium ions in said milk and/or milk product ranges from 8 mM to 25 mM, and methods of producing the same, are provided.

Abstract: The invention provides compositions comprising at least one cannabinoid compound, for use in the method of treating and preventing a disease, condition or symptom caused by, or associated with fungi, bacteria and microbes.

Abstract: A composition comprising at least one sugar alcohol and a population of viable probiotic bacteria belonging to the class Bacilli is disclosed. The product is devoid of sugar or comprises no more than 5% of the amount of said sugar alcohol in the composition, the composition being formulated for oral delivery.

Abstract: The present invention discloses liquid precursor compositions adapted for application on a hard surface in the oral cavity, comprising at least one therapeutic agent suitable for the treatment of oral disorders, at least one acidic-pH sensitive polymer, at least one hydrophobic polymer, and a pharmaceutically acceptable volatile carrier, wherein a weight ratio between said at least one hydrophobic polymer and said at least one acidic-pH sensitive polymer is larger than 1. The invention also discloses formulations formed of the solidification of these compositions, and methods for treating oral disorders by applying these compositions on hard surfaces in the oral cavity or to be placed in the oral cavity.

Abstract: The present invention discloses a method of treating a head and neck cancer or preventing the development of pre-malignant lesions to this cancer, by administering locally to the oral cavity, a sustained release drug delivery system comprising a drug for the treatment of this cancer or for the prevention of said lesions, and at least one polymer, such that said system is attached to a surface in the oral cavity and remains attached thereto for at least 1 hour, accompanied by release of the drug and maintaining an effective therapeutic concentration thereof in the cavity, for at least 1 hour. Further are disclosed a sustained release drug delivery system and a liquid precursor varnish composition to this system.

Abstract: Provided herein injectable implant compositions useful for acceleration of bone fracture healing, treatment of dental or oral pathologies, and controlled drug delivery.

Abstract: Compositions comprising magnesium enriched liquids re provided. Specifically, compositions comprising magnesium enriched milk and/or milk product, wherein a concentration of magnesium ions in said milk and/or milk product ranges from 8 mM to 25 mM, and methods of producing the same, are provided.

Abstract: The present invention discloses a liquid precursor composition adapted for application on a on a desired surface, this composition comprising: a. at least one therapeutic agent suitable for the treatment or prevention of a disorder or pathological condition, wherein said disorder or pathological condition excludes oral disorders, b. at least one acidic-pH sensitive polymer, c. at least one hydrophobic polymer, and d. a pharmaceutically acceptable volatile solvent, wherein a weight ratio between the at least one hydrophobic polymer and the at least one acidic-pH sensitive polymer is larger than 1.

Abstract: The present invention discloses a liquid precursor composition adapted for application on a on a desired surface, this composition comprising: a. at least one therapeutic agent suitable for the treatment or prevention of a disorder or pathological condition, wherein said disorder or pathological condition excludes oral disorders, b. at least one acidic-pH sensitive polymer, c. at least one hydrophobic polymer, and d. a pharmaceutically acceptable volatile solvent, wherein a weight ratio between the at least one hydrophobic polymer and the at least one acidic-pH sensitive polymer is larger than 1.

Abstract: Novel agents exhibiting anti-biofilm formation activity while being non-cytotoxic are provided, as well as methods of using the same, either per se or conjugated to a polymer, for preventing and/or reducing the formation of microbial biofilms and/or for disrupting microbial biofilms. The novel agents described herein include thiazolidine-2,4-diones (TZDs), pyrrolidine-2,5-diones (PYDs), imidazolidine-2,4-diones or oxazolidine-2,4-diones, substituted by an alkyl having 7-20 carbon atoms in its backbone chain.

Abstract: The present invention discloses a method of treating a head and neck cancer or preventing the development of pre-malignant lesions to this cancer, by administering locally to the oral cavity, a sustained release drug delivery system comprising a drug for the treatment of this cancer or for the prevention of said lesions, and at least one polymer, such that said system is attached to a surface in the oral cavity and remains attached thereto for at least 1 hour, accompanied by release of the drug and maintaining an effective therapeutic concentration thereof in the cavity, for at least 1 hour. Further are disclosed a sustained release drug delivery system and a liquid precursor varnish composition to this system.

Abstract: The present invention discloses liquid precursor compositions adapted for application on a hard surface in the oral cavity, comprising at least one therapeutic agent suitable for the treatment of oral disorders, at least one acidic-pH sensitive polymer, at least one hydrophobic polymer, and a pharmaceutically acceptable volatile carrier, wherein a weight ratio between said at least one hydrophobic polymer and said at least one acidic-pH sensitive polymer is larger than 1. The invention also discloses formulations formed of the solidification of these compositions, and methods for treating oral disorders by applying these compositions on hard surfaces in the oral cavity or to be placed in the oral cavity.

Abstract: Novel agents exhibiting anti-biofilm formation activity while being non-cytotoxic are provided, as well as methods of using the same, either per se or conjugated to a polymer, for preventing and/or reducing the formation of microbial biofilms and/or for disrupting microbial biofilms. The novel agents described herein include thiazolidine-2,4-diones (TZDs), pyrrolidine-2,5-diones (PYDs), imidazolidine-2,4-diones or oxazolidine-2,4-diones, substituted by an alkyl having 7-20 carbon atoms in its backbone chain.

Abstract: A liquid lithium jet nozzle comprising: an inlet through which liquid lithium flows into the nozzle; an inlet flow channel that receives liquid lithium that flows into the nozzle via the inlet and shapes the flowing liquid lithium to flow in a thin film; and a flow region that receives flowing liquid lithium shaped by the flow channel and in which the liquid lithium flows with at least one large surface of the film exposed.

Abstract: Disclosed are chewing gums that are organoleptically acceptable, and have high adherence to plaque bacteria. A chewing gum according to an exemplary embodiment contains a gum base, at least one edible acid, and optionally other ingredients. The invention also provides a method for preparing a chewing gum composition, which includes triturating of coloring agent, and a method for commercially producing and marketing chewing gums, which includes testing the chewing gums for adhesion to bacteria, such as plaque bacteria.

Abstract: The invention relates to a composition for modulation of at least one bacteria-related parameter comprising oxazaborolidine derivative compounds. The invention additionally relates to new oxazaborolidine derivative compounds. The invention further relates to a composition for decreasing bacterial growth, a composition for increasing the susceptibility of bacteria to the cytotoxic effects of other antibacterial agents, and a pharmaceutical composition comprising as an active ingredient an oxazaborolidine derivative compound. Methods for modulating at least one bacteria-related parameter, for preventing, decreasing or eliminating bacterial growth, and for making bacteria more susceptible to other antibacterial compounds are also described.

Abstract: An edible and/or chewable article of manufacture containing at least one food grade substance having adsorption affinity towards at least one dental plaque (biofilm) constituent and capable of reducing and/or removing the oral biofilm while present in the mouth. Particular articles of manufacture are chewing gums, sweets, candies, candy, and other nutritional bars, ice creams, chocolates, confectionery and bakery/pastry products, honey, dairy products and beverages, and oral hygiene products such as tooth pastes, oral gels and mouthwashes. A chewing gum having a conventional gum base and at least one food grade active substance having adsorption affinity towards at least one dental plaque (biofilm) constituent (bacteria and proteins and bacterial cell-free enzymes) and capable of reducing and/or removing the oral biofilm while present in the mouth.

Abstract: The present invention pertains to biodegradable sustained-release composins capable of achieving the sustained release of a pharmaceutical or other agent. The compositions can be formed into implant devices which may be used to treat a wide variety of diseases and conditions. The implants are especially useful in treating diseases such as periodontal disease which require prolonged drug release.